右美托咪定用于鞘内注射的研究进展  

Progress of dexmedetomidine for intrathecal injection

作　　者：刘淑娇 张全意[1] Liu Shujiao;Zhang Quanyi(Department of Anesthesiology,Binzhou Medical University Hospital,Binzhou 256600,China)

机构地区：[1]滨州医学院附属医院麻醉科,滨州256603

出　　处：《国际医药卫生导报》2024年第3期362-366,共5页International Medicine and Health Guidance News

摘　　要：为提高麻醉质量,减少鞘内局麻药的用量,进而降低不良反应发生率,鞘内局麻药与鞘内辅助药物的应用越来越受到关注。右美托咪定作为一种高选择性、特异性和强效性的α2-肾上腺素能受体激动剂一直是研究的热点药物,其镇痛效果已在各种手术中得到证实,但其鞘内应用的镇痛机制及安全性问题仍然是临床研究的难点。为更好提高麻醉质量,促进医疗事业的进步,本综述就右美托咪定用于鞘内注射的研究进展进行阐述。In order to improve the quality of anesthesia,reduce the amount of intrathecal local anesthetics,and decrease the incidence of adverse reactions,the application of intrathecal local anesthetics and intrathecal adjuvant drugs has received more and more attention.Dexmedetomidine,as a kind of highly selective,specific,and potentα2-adrenergic agonist,has been a hotspot drug in research.Its analgesic effects have been proved in a variety of surgeries,but the analgesic mechanism of its intrathecal application and the issue of safety are still difficult problems in the clinical research.In order to better improve the quality of anesthesia and promote the advancement of the medical cause,the review on the progress of the research on the use of dexmedetomidine for intrathecal injection is described。

关 键 词：右美托咪定 鞘内注射 进展 

分 类 号：R614[医药卫生—麻醉学]